NasdaqGS - Delayed Quote USD
176.27 -5.76 (-3.16%)
At close: August 28 at 4:00:00 PM EDT
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Chart Range Bar
Loading chart for RGEN
- Previous Close 182.03
- Open 179.76
- Bid 176.08 x 100
- Ask 178.06 x 100
- Day's Range 175.70 - 181.35
- 52 Week Range 100.99 - 188.73
- Volume 818,689
- Avg. Volume 1,105,252
- Market Cap (intraday) 9.948B
- Beta (5Y Monthly) 1.01
- PE Ratio (TTM) 244.82
- EPS (TTM) 0.72
- Earnings Date Nov 3, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est 185.70
Trailing total returns as of 8/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
RGEN
7.57%
S&P 500 (^GSPC)
12.65%
1-Year Return
RGEN
44.28%
S&P 500 (^GSPC)
18.61%
3-Year Return
RGEN
6.11%
S&P 500 (^GSPC)
73.95%
5-Year Return
RGEN
36.09%
S&P 500 (^GSPC)
71.02%
Valuation Measures
As of 8/27/2026
Market Cap
10.27B
Enterprise Value
10.15B
Trailing P/E
249.36
Forward P/E
88.50
PEG Ratio (5yr expected)
2.43
Price/Sales (ttm)
13.13
Price/Book (mrq)
4.86
Enterprise Value/Revenue
12.93
Enterprise Value/EBITDA
59.17
Financial Highlights
Profitability and Income Statement
Profit Margin
5.29%
Return on Assets (ttm)
1.39%
Return on Equity (ttm)
1.99%
Revenue (ttm)
785.1M
Net Income Avi to Common (ttm)
41.54M
Diluted EPS (ttm)
0.72
Balance Sheet and Cash Flow
Total Cash (mrq)
810.45M
Total Debt/Equity (mrq)
32.71%
Levered Free Cash Flow (ttm)
113.42M
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
176.27 Current
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
0 Low
Sector Avg.
100 High
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
0 Low
Sector Avg.
100 High
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
0 Low
Sector Avg.
100 High
Raising target price to $191.00
REPLIGEN CORP has an Investment Rating of HOLD; a target price of $191.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
Rating
Price Target
Raising target price to $174.00
REPLIGEN CORP has an Investment Rating of HOLD; a target price of $174.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
Rating
Price Target
Raising target price to $173.00
REPLIGEN CORP has an Investment Rating of HOLD; a target price of $173.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
Rating
Price Target
Repligen Earnings: Excellent Profit Margins, China Recovery Underway
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Rating
Price Target